Latest News

Source: magnific.com  Ask ten UK traders which broker is best and you'll get a range of answers, because the "best" broker genuinely depends on how someone trades. But when you assess brokers against the criteria that matter most to the widest range of UK traders — regulation, track record, execution quality, platform choice and market [...]

Bolt promised to buy 100,000 Lucids, but can it afford them?

One company is growing at a pace that is almost impossible to find in semiconductors. The other has reinvented itself as a contracted AI infrastructure play with billions in guaranteed revenue.

HubSpot (NYSE:HUBS) used its Analyst Day at UNBOUND to outline an AI-focused strategy centered on what Chief Executive Officer Yamini Rangan called the “outcomes era,” in which software companies are measured less by features and more by their ability to produce measurable business results for custo

This under-the-radar cybersecurity stock boasts a Superscore of 78 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

The struggling stock's underlying business isn't quite in the dire straits most investors seem to think it is.

Should you take the market's small discount now, or hold out for a bigger one?

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.

Andrew Micallef reduced his stake to 7,942 shares.

The microreactor maker has a promising future, but it's also richly valued.

Astera Labs is riding explosive demand for AI connectivity chips with gross margins above 70%. Arm is compounding royalty revenue across billions of devices while its data center business accelerates.

The Dow is down 2% this week. The Nasdaq is up. One of the indexes is reading the Fed policy wrong.

This company has had plenty of setbacks in recent years, but it generally bounces back.

How does the market typically perform after a new rate hike cycle begins?

The AI developer is reportedly gearing up for an initial public offering this fall at a valuation near $2 trillion.

BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley

After raising more capital earlier this year, Ackman and his team purchased several new stocks in the second quarter of the year.

What Happened? Shares of network chips maker MACOM Technology Solutions (NASDAQ: MTSI) jumped 4.6% in the afternoon session after BMO Capital upgraded the se...

What Happened? Shares of enterprise software giant Oracle (NYSE:ORCL) fell 3.4% in the afternoon session after Business Insider reported that co-CEO Clay Mag...

What Happened? Shares of electricity storage and software provider Fluence (NASDAQ:FLNC) fell 5.3% in the afternoon session after Jefferies downgraded the co...

What Happened? Shares of global professional services company Accenture (NYSE:ACN) fell 3.3% in the afternoon session after Guggenheim analyst Jonathan Lee d...

What Happened? Shares of water control and measurement company Badger Meter (NYSE:BMI) jumped 4.2% in the afternoon session after Northcoast analyst Ryan Con...

What Happened? A number of stocks jumped in the afternoon session after the SEC announced a five-year conditional Innovation Exemption allowing eligible plat...

What Happened? Shares of streaming video giant Netflix (NASDAQ: NFLX) fell 5% in the afternoon session after Wells Fargo analyst Steven Cahall downgraded the...